| |
ARTICLE |
TYPE |
ABSTRACT |
PDF |
Pages |
| |
CURRENT ISSUE |
 |
Developing new targeted drugs for resectable gastric cancer |
EDITORIAL |
|
|
1-7 |
| |
Pancreatic cancer genome analysis. New predictive approaches. |
NEWS & VIEWS |
|
|
8-14 |
| |
Developing personalized novel therapies for pancreatic cancer. |
NEWS & VIEWS |
|
|
15-20 |
| |
Validation of the Memorial Sloan-Kettering Cancer Center nomogram in the prediction of recurrence risk after treatment in Ductal Carcinoma in Situ of the breast. Rolex Replica Watches www.usreplicas.com
|
Original Article |
|
|
21-30 |
| |
Static and dynamic analysis with Next-Generation Sequencing. |
FOCUS |
|
|
31-36 |
| |
Recent approval of new targeted drugs for non-metastatic cancers improves oncological outcomes. |
FOCUS |
|
|
37-42 |
| |
Breakthrough blood test for early diagnosis, screening, patient monitoring and therapeutic response prediction. |
Special Report |
|
|
43-48 |
| |
Genome analysis for the development of novel gastric cancer biomarkers. |
Special Report |
|
|
49-54 |
| |
Trastazumab – emtasine for HER2-positive breast cancer patients and development of new therapies. |
PERSPECTIVE |
|
|
55-70 |
